Thomas Schuetz

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Philip W. Kantoff, Thomas Schuetz, Brent A. Blumenstein et al. · Journal of Clinical Oncology · 2010 · 973 citations

Medicine, Immunology, Oncology +17

A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)

Joseph Muenzer, Müge Güçsavaş‐Çalıkoğlu, Shawn E. McCandless et al. · Molecular Genetics and Metabolism · 2006 · 215 citations

Life Sciences, Biochemistry, Clinical Biochemistry +8

A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer

R. Dipaola, Mark Plante, Howard L. Kaufman et al. · Journal of Translational Medicine · 2006 · 192 citations · Full text

Medicine, Immunology, Oncology +17

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

David Monteith, Emily C. Collins, Corinne Vandermeulen et al. · Frontiers in Pharmacology · 2017 · 65 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity

Uğur Eskiocak, Wilson Guzman, Benjamin Wolf et al. · JCI Insight · 2020 · 47 citations · Full text

Life Sciences, Immunology, Pharmacology +17